vaccin
effici
way
control
epidem
caus
infecti
pathogen
best
exemplifi
edward
jenner
discoveri
show
infect
human
cowpox
viru
gener
crossprotect
immun
respons
infect
human
variola
viru
caus
sever
smallpox
epidem
centuri
consequ
worldwid
vaccin
program
umbrella
world
health
organ
final
led
erad
smallpox
sinc
antibodybas
vaccin
multipl
human
virus
caus
pandem
diseas
develop
includ
influenza
hepat
b
polio
papilloma
yellow
fever
measl
etc
realli
erad
viral
infect
besid
clinic
efficaci
vaccin
global
polit
econom
power
implement
vaccin
worldwid
popul
vulner
respect
viru
fortun
increas
scientif
knowledg
viral
pathogen
methodolog
progress
molecular
techniqu
viral
vector
acceler
vaccin
develop
recent
exemplifi
develop
vaccin
ebola
viru
strain
respons
outbreak
west
africa
furthermor
coalit
epidem
prepard
innov
cepi
consist
academia
industri
compani
govern
public
health
agenc
establish
recent
priorit
streamlin
preclin
develop
new
vaccin
emerg
potenti
epidem
virus
middl
east
respiratori
syndrom
mer
lassa
nipah
conceptu
activ
passiv
immun
distinguish
figur
activ
immun
base
antigen
compon
respect
pathogen
upon
introduct
bodi
either
natur
infect
vaccin
gener
week
natur
longlast
adapt
immun
respons
abl
neutral
protect
infect
correspond
antigen
process
antigenpres
cell
apc
expos
pathogenspecif
peptid
major
histocompat
complex
mhc
type
ii
activ
cytotox
helper
tcell
respect
figur
natur
immun
respons
also
includ
gener
longliv
memori
b
cell
rapidli
activ
expand
upon
next
encount
pathogen
contrast
passiv
immun
consist
direct
administr
protect
antibodi
extern
sourc
provid
immedi
shortliv
protect
due
limit
halflif
antibodi
three
week
passiv
immun
also
occur
natur
ie
transfer
antibodi
mother
child
via
placenta
breast
milk
occur
artifici
transfer
purifi
natur
recombinantli
express
antibodi
directli
patient
exampl
infect
prevent
passiv
vaccin
rabi
tetanu
hepat
differ
type
vaccin
gener
long
histori
vaccin
develop
figur
initi
whole
microorgan
use
either
live
attenu
killedinactiv
form
due
replic
capac
live
attenu
microorgan
abl
gener
effici
longlast
immun
respons
upon
vaccin
howev
immunocompromis
patient
attenu
microorgan
may
revert
initi
replic
potenti
eventu
caus
diseas
matter
concern
oral
polio
vaccin
tuberculosi
vaccin
bacillu
bcg
viral
relat
diseas
like
measl
mump
rubella
yellow
fever
etc
live
attenu
virus
still
use
vaccin
rabi
vaccin
contrast
base
inactiv
form
viru
safeti
reason
follow
technic
advanc
allow
fast
sequenc
pathogen
genom
recombin
express
antigen
subunit
vaccin
also
develop
mostli
compos
surfac
compon
pathogen
antigen
compon
often
involv
infect
process
ie
receptorbind
also
easili
access
neutral
antibodi
subunit
vaccin
may
also
involv
modifi
toxin
toxoid
encod
microorgan
prevent
toxic
pathogen
effect
vaccin
often
use
combin
ie
combin
toxoid
vaccin
diphteria
whoop
cough
pertussi
tetanu
dpt
advantag
subunit
vaccin
view
diagnosi
viral
infect
vaccin
person
distinguish
infect
person
serolog
level
due
restrict
antibodi
respons
direct
subunit
vaccin
highli
variabl
pathogen
like
influenza
virus
combin
vaccin
immunogen
use
cover
divers
viral
strain
aris
antigen
drift
occasion
new
introduct
anim
reservoir
requir
contin
monitor
circul
influenza
viru
strain
recent
describ
comput
predict
tool
order
abl
predict
amino
acid
chang
avian
influenza
virus
may
chang
tropism
avian
sialic
acid
receptor
toward
human
sialic
acid
receptor
next
influenza
season
parallel
attempt
achiev
broad
coverag
influenza
virus
univers
vaccin
also
focuss
identif
conserv
epitop
viru
surfac
protein
build
envelop
spike
essenti
infect
virus
spike
compos
trimer
viral
hemagglutinin
ha
divid
highli
variabl
globular
head
contain
receptorbind
site
conserv
stalk
domain
respons
fusion
chimer
ha
antigen
comput
optim
broadli
reactiv
antigen
cobra
base
multipl
ancestr
ha
sequenc
gener
shown
protect
divers
anim
model
influenza
viru
infect
recent
identif
whole
seri
monoclon
broadli
neutral
antibodi
bnab
facilit
introduct
new
highthroughput
techniqu
antigen
specif
bcell
sort
infect
patient
downstream
character
correspond
target
epitop
contribut
significantli
identifi
function
structur
conserv
epitop
potenti
suit
univers
vaccin
although
bnab
target
globular
domain
bnab
target
conserv
though
less
immunogen
domain
implic
membran
fusion
region
shown
induc
antibodi
broad
potent
antibodydepend
cellular
cytotox
adcc
activ
contrast
less
broad
neutral
antibodi
target
globular
head
ha
thu
engin
miniha
stem
antigen
abl
induc
antibodi
protect
mice
lethal
heterolog
challeng
model
also
virus
like
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
recombinantli
express
receptorbind
domain
spike
protein
could
protect
sarscov
challeng
anim
model
even
smaller
spike
compon
epitop
vaccin
mimic
conserv
function
import
domain
otherwis
highli
variabl
surfac
protein
viru
essenti
infect
ideal
case
adapt
immun
respons
gener
upon
vaccin
epitop
keep
viru
check
escap
mutat
essenti
epitop
would
sever
compromis
infect
viru
howev
epitop
often
correspond
conform
epitop
ie
compos
protein
stretch
separ
linear
protein
sequenc
juxtapos
tertiari
protein
structur
even
threedimension
structur
envelop
compon
known
rebuild
conform
epitop
natur
function
form
still
challeng
separ
protein
context
furthermor
inclus
addit
vaccinerelev
domain
like
cell
epitop
tolllik
receptor
tlr
agonist
adjuv
linker
compon
complic
expect
vaccin
outcom
better
predict
epitop
vaccin
base
antigen
process
proteasom
transport
endoplasmat
reticulum
er
tap
antigen
peptid
transport
mhc
bind
multipl
silico
approach
develop
nevertheless
epitopebas
vaccin
still
infanc
clinic
vaccin
trial
pipelin
respect
infecti
diseas
epitopebas
malaria
vaccin
rt
mosquirixtm
develop
base
express
contigu
immunogen
epitop
predomin
surfac
antigen
plasmodium
falciparum
involv
attach
circumsporozoit
protein
csp
liver
cell
epitop
present
hepat
b
surfac
antigen
hbsag
viruslik
particl
platform
vaccin
partial
effect
larg
phase
iii
trial
involv
children
howev
protect
wane
time
also
influenza
virus
univers
epitopebas
vaccin
develop
contain
nine
conserv
b
cell
epitop
influenza
b
virus
vaccin
recent
enter
clinic
phase
iib
phase
iii
studi
plan
produc
compani
biondvax
epitop
express
singl
recombin
protein
kda
e
coli
infect
spread
worldwid
particular
last
year
caus
one
major
recent
epidem
affect
human
total
million
peopl
infect
million
die
due
hivaid
due
predominantli
sexual
transmiss
primarili
infect
younger
gener
devast
econom
consequ
famili
countri
affect
region
subsaharan
africa
worldwid
effort
initi
joint
unit
nation
programm
hivaid
unaid
partner
achiev
agenda
aim
diagnos
hiv
infect
antiretrovir
treatment
art
result
viral
suppress
individu
current
million
person
live
worldwid
although
number
new
infect
declin
mani
countri
due
broader
avail
art
million
new
infect
still
regist
well
million
hivrel
death
furthermor
despit
huge
success
art
treatment
prevent
infect
worldwid
region
like
eastern
europ
middl
east
actual
experienc
strong
increas
new
infect
problem
except
hiv
prevent
program
recent
appli
cohort
high
risk
infect
vast
major
art
given
person
diagnos
infect
statu
howev
even
higher
incom
countri
hivinfect
person
awar
infect
person
like
spread
viru
among
contact
absenc
art
higher
viral
load
increas
probabl
hiv
transmiss
figur
therefor
intensif
test
essenti
order
abl
initi
art
earli
prevent
transmiss
fact
mani
peopl
unawar
infect
also
due
natur
viru
belong
genu
lentiviru
within
famili
retrovirida
integr
provir
dna
gener
revers
transcript
rna
genom
shortli
infect
human
chromosom
infect
cell
persist
year
latent
state
reactiv
extern
stimuli
furthermor
infect
often
caus
obviou
specif
sign
hivrel
diseas
first
year
infect
person
unawar
infect
thu
persist
incognito
lowlevel
replic
absenc
art
therefor
order
prevent
transmiss
hiv
vaccin
still
urgent
need
effect
vaccin
would
prevent
transmiss
donor
recipi
irrespect
serolog
statu
furthermor
effect
vaccin
could
substitut
administr
antivir
drug
prevent
infect
healthi
peopl
risk
vaccin
develop
one
major
challeng
medic
research
due
high
mutabl
mutationsgenomerepl
cycl
evolv
uniqu
arsen
trick
evad
immun
system
figur
infect
primarili
helper
cell
play
pivot
role
adapt
immun
system
activ
b
cell
cytotox
cell
via
costimulatori
molecul
cytokin
secret
infect
cell
kill
infect
cell
viru
product
also
kill
uninfect
cell
via
bystand
mechan
one
mechan
describ
section
earli
replic
lymphat
tissu
lymph
node
gut
target
cell
densli
pack
togeth
antigenpres
cell
destroy
architectur
function
lymph
node
thu
infect
elimin
time
central
cell
type
organ
immun
system
final
result
acquir
immunodefici
aid
death
absenc
art
howev
process
take
time
integr
persist
silent
low
replic
level
latter
allow
viru
mutat
escap
immun
respons
host
outlin
influenza
virus
viral
variabl
major
problem
vaccin
develop
variabl
far
exce
influenza
virus
one
singl
person
infect
viru
type
caus
worldwid
hiv
infect
variabl
six
year
infect
correspond
global
variabl
influenza
virus
circul
one
year
besid
two
hiv
type
variou
subtyp
differ
env
amino
acid
sequenc
continu
evolv
within
infect
person
driven
high
error
rate
viral
revers
transcriptas
final
result
quasispeci
relat
genom
diverg
singl
patient
besid
fool
immun
system
major
aberr
viru
particl
function
high
variabl
allow
mutant
virus
escap
select
pressur
impos
immun
system
antivir
drug
function
form
mechan
immun
evas
mediat
natur
nativ
env
spike
viral
surfac
mediat
infect
receptor
bind
fusion
major
target
virusneutr
antibodi
nativ
env
spike
trimer
three
heterodim
compos
outer
envelop
glycoprotein
transmembran
glycoprotein
deriv
common
precursor
glycoprotein
half
mass
glycoprotein
compos
sugar
cover
outer
surfac
spike
particular
variabl
loop
reduc
immunogen
viru
particl
furthermor
wherea
hundr
spike
present
influenza
virus
particl
usual
contain
spike
averag
low
number
enough
infect
minim
particl
immunogen
addit
spike
unstabl
compon
trimer
spike
noncoval
link
result
shed
compon
monomer
protein
nonn
conform
compar
spikeassoci
counterpart
well
stump
left
viral
surfac
mislead
immun
system
produc
antibodi
immunodomin
nonfunct
env
form
final
trimer
env
spike
fix
conform
character
tremend
flexibl
nativ
close
form
shift
toward
open
conform
addit
sequenti
bind
two
differ
receptor
necessari
activ
fusion
event
viral
cellular
membran
wherebi
bind
first
receptor
trigger
conform
chang
lead
exposur
coreceptor
bind
epitop
either
bind
howev
period
viru
alreadi
close
cellular
membran
mani
antibodi
particular
membraneproxim
extern
region
mper
hardli
interfer
infect
evas
trick
fool
immun
system
also
research
involv
hiv
vaccin
research
decad
thu
initi
vaccin
trial
base
solubl
monomer
often
deriv
cultureadapt
strain
know
today
due
nonn
conform
suit
induc
broadli
neutral
antibodi
bnab
ie
antibodi
abl
neutral
broad
spectrum
primari
strain
belong
differ
subtpy
best
vaccin
could
induc
antibodi
neutral
autolog
strain
nevertheless
learnt
mani
lesson
major
advanc
field
obtain
solubl
mimet
nativ
trimer
env
spike
sosip
ration
design
base
structur
function
analys
immunogen
optim
recent
year
yet
bnab
primari
heterolog
strain
induc
far
upon
vaccin
either
rabbit
monkey
human
best
antibodi
neutral
autolog
primari
strain
obtain
howev
interest
find
upon
immun
camelid
broadli
neutral
nanobodi
correspond
variabl
domain
heavi
chainonli
antibodi
could
induc
recent
studi
immun
dromedari
solubl
trimer
subtyp
c
protein
two
nanobodi
complementari
neutral
pattern
obtain
neutral
primari
strain
standard
panel
across
differ
subtyp
interestingli
immun
cow
sosip
also
result
broadli
neutral
antibodi
camelid
cow
produc
antibodi
longer
heavychain
complementari
determin
region
often
featur
bnab
contrast
difficulti
encount
attempt
induc
bnab
vaccin
studi
bnab
gener
natur
chronic
infect
subset
posit
patient
base
new
technic
develop
like
antigenspecif
b
cell
sort
patient
plethora
bnab
character
recent
year
summar
bnaber
databas
detail
character
reveal
peculiar
featur
like
high
degre
affin
matur
long
heavi
chain
complementaritydetermin
region
hcdr
loop
sometim
autoreact
furthermor
bnab
show
protect
therapeut
effici
human
mous
model
monkey
first
bnab
clinic
trial
shown
reduc
viremia
delay
viral
rebound
upon
therapeut
applic
base
promiss
result
optim
sosip
immunogen
ongo
aim
achiev
induct
bnab
particular
immunogen
abl
engag
b
cell
sequenti
activ
relat
sosip
construct
final
lead
induct
highaffin
matur
bnab
synthet
peptid
strategi
develop
mimic
function
import
site
viral
env
spike
use
immunogen
activ
vaccin
approach
bind
site
essenti
viru
entri
cell
promis
target
interfer
viru
entri
fact
rang
bnab
isol
infect
individu
shown
recogn
epitop
overlap
therefor
synthet
mimic
initi
thought
adequ
immunogen
elicit
broadli
neutral
immun
respons
similar
natur
bnab
recogn
gener
synthet
compar
recombinantli
gener
peptid
use
tool
mimicri
protein
site
includ
epitop
antibodi
sinc
present
natur
protein
fragment
also
allow
divers
chemic
modif
includ
incorpor
larg
rang
nonproteinogen
amino
acid
apart
extend
chemic
structur
divers
present
peptid
modif
also
increas
proteolyt
stabil
molecul
enhanc
potenti
drug
candid
base
first
publish
crystal
structur
complex
previous
design
assembl
peptid
present
three
fragment
ie
bind
loop
strand
strand
concertedli
constitut
figur
left
antisera
obtain
immun
rabbit
peptid
specif
recogn
furthermor
antisera
compet
mab
whose
epitop
overlap
bind
howev
antisera
found
virusneutr
sinc
vitro
bind
assay
demonstr
inhibit
interact
recombin
monomer
solubl
anticip
would
abl
inhibit
interact
also
context
infect
thu
prevent
infect
cell
contrari
expect
found
strongli
specif
enhanc
infect
target
cell
moreov
shown
peptid
also
enabl
infect
otherwis
unsuscept
cell
like
aggreg
fibril
format
strongli
contribut
effect
observ
believ
abil
trigger
infect
cell
point
addit
mechan
induct
conform
chang
within
env
may
facilit
infect
base
observ
shown
specif
interact
protein
differ
strain
mediat
fragment
correspond
strand
approach
follow
idea
revers
vaccinolog
zwick
et
al
identifi
mimotop
ie
peptid
select
recogn
antibodi
screen
phagedisplay
librari
unlik
mimet
peptid
howev
mimotop
peptid
unabl
elicit
reactiv
immun
respons
use
immunogen
mice
env
region
also
use
templat
design
peptid
immunogen
includ
prehairpin
intermedi
well
mper
goal
elicit
neutral
antibodi
target
transient
viral
entri
intermedi
bianci
et
al
use
rang
peptid
deriv
nhr
region
immunogen
vaccin
guinea
pig
result
polyclon
antisera
shown
neutral
tier
isol
vitro
structurebas
revers
vaccinolog
approach
serrano
et
al
design
peptid
immunogen
base
epitop
broadli
neutral
antibodi
locat
mper
immun
rabbit
peptid
combin
liposom
elicit
crossreact
immun
respons
synthet
peptid
mimic
also
deriv
antibodi
paratop
ie
region
antibodi
specif
recogn
correspond
antigen
via
complementaritydetermin
region
cdr
surfac
variabl
domain
heavi
light
chain
molecul
mimic
cdr
antibodi
therefor
expect
mimic
bind
specif
antibodi
consequ
effect
prevent
interact
diseaseassoci
protein
ligand
figur
right
recent
report
paratop
mimet
peptid
broadli
neutral
antibodi
describ
antibodi
recogn
envelop
glycoprotein
effici
neutral
infect
vitro
vivo
base
crystal
structur
complex
design
assembl
peptid
present
three
heavi
chain
cdr
thu
contact
site
antibodi
figur
right
bottom
mimet
peptid
shown
bind
submicromolar
concentr
well
inhibit
infect
demonstr
function
mimicri
paratop
mimet
peptid
furthermor
mimet
peptid
abl
discrimin
support
notion
function
mimicri
peptid
besid
synthet
approach
epitop
mimic
bnab
patient
sera
also
identifi
phage
display
technolog
phage
librari
present
random
peptid
sequenc
shotgunclon
larger
env
fragment
screen
immunoglobulin
hivposit
sera
neutral
activ
bnab
often
target
conform
epitop
special
softwar
develop
analyz
whether
select
linear
mimotop
sequenc
without
obviou
linear
homolog
env
could
repres
conform
epitop
env
surfac
interestingli
select
mimotop
could
induc
weak
hivneutr
antibodi
mice
vaccin
mimotop
phage
context
also
outsid
phage
coupl
differ
carrier
recent
year
two
interest
linear
epitop
sequenc
identifi
transmembran
protein
figur
discuss
detail
due
clinic
relev
hiv
epitop
vaccin
develop
also
contain
addit
epitop
neutral
ab
like
firstgener
mab
potent
bnab
local
mper
origin
epitop
identifi
screen
envtailor
phage
display
librari
plasma
antibodi
elit
control
show
neutral
activ
tier
ie
neutralizationresist
patient
strain
epitop
amino
acid
overlap
clearli
differ
epitop
first
gener
mab
could
show
epitop
inde
respons
neutral
activ
plasma
preabsorpt
plasma
epitop
coupl
affin
column
reduc
neutral
activ
ii
plasma
antibodi
affinitypurifi
epitop
neutral
activ
iii
immun
epitop
coupl
differ
carrier
induc
neutral
antibodi
mice
mper
antibodi
like
mab
often
show
autoreact
due
partial
integr
epitop
membran
epitop
optim
determin
core
epitop
amino
acid
target
neutral
antibodi
avoid
autoreact
phospholipid
import
view
vaccin
studi
autoreact
may
lead
elimin
antibodyproduc
cell
b
cell
ontolog
peripheri
immun
mice
optim
peptid
env
dna
primepeptid
boost
approach
induc
tier
neutral
antibodi
without
crossreact
cardiolipin
experi
underlin
suitabl
epitop
potenti
epitop
vaccin
candid
induct
antibodi
neutral
also
tier
strain
shown
suit
anim
model
also
support
clinic
data
show
higher
proport
sera
longterm
nonprogressor
ltnp
cohort
treat
art
react
peptid
compar
sera
treat
cohort
furthermor
treat
cohort
close
sera
patient
antibodi
earli
late
stage
infect
higher
nadir
accord
us
center
diseas
control
cdc
determin
clinic
stage
hiv
infect
thu
antibodi
target
epitop
may
benefici
patient
epitop
advanc
respect
clinic
develop
highli
conserv
motif
interact
receptor
globular
form
complement
factor
therebi
induc
express
cellular
ligand
activ
natur
killer
nk
receptor
render
uninfect
cell
sensit
nk
cell
lysi
posit
patient
mechan
action
compos
success
step
outlin
figur
express
ligand
strongli
correl
diseas
progress
declin
count
motif
character
high
level
conserv
strain
differ
clade
although
ab
neutral
viru
produc
human
earli
stage
infect
invers
correl
cellcount
decreas
result
retrospect
studi
includ
untreat
seropositv
patient
reveal
presenc
high
ab
level
time
seroconvers
factor
predict
cell
protect
first
three
year
infect
independ
rna
dna
viral
load
uniqu
properti
serv
cornerston
develop
vaccin
strategi
prevent
cell
deplet
subsequ
side
effect
immun
activ
inflamm
concept
valid
nonhuman
primat
nhp
model
success
test
phase
iiia
clinic
trial
hivinfect
patient
antiretrovir
therapi
collabor
innavirvax
uniqu
properti
peptid
studi
alaninewalk
motif
specif
substitut
posit
call
abl
elicit
bnab
crossclad
viral
neutral
properti
mice
immun
peptid
collabor
gabriella
scarlatti
milan
itali
observ
bnab
unparallel
magnitud
breadth
abil
confer
specif
effect
durabl
tier
tier
virus
differ
clade
b
c
e
moreov
two
set
data
rabbit
macaqu
demonstr
abil
peptid
induc
bnab
larger
anim
model
altogeth
data
demonstr
antigen
interest
natur
ab
also
observ
patient
high
count
immunepurif
peptid
ab
serum
patient
abl
neutral
high
titer
tier
virus
clade
b
c
e
interestingli
presenc
bnab
strongli
increas
untreat
longterm
nonprogressor
ltnp
patient
french
alt
cohort
agenc
national
de
recherch
sur
le
sida
anr
compar
hiv
progressor
patient
vs
suggest
specif
bnab
like
associ
lack
diseas
progress
neutral
capac
invers
correl
viral
load
provir
dna
associ
preserv
count
cell
ltnp
patient
produc
specif
bnab
could
specif
recogn
antigen
hiv
recal
antigen
conceiv
bnab
particip
protect
patient
continu
virolog
control
result
mainten
tcell
count
function
studi
provid
strong
argument
bnab
contribut
ltnp
statu
although
vivo
immun
passivetransf
experi
purifi
ab
alon
combin
epitop
like
optim
peptid
describ
investig
nonhuman
primat
model
determin
protect
valu
driven
recent
success
viral
vector
vivo
gene
therapi
novel
concept
emerg
confer
protect
hiv
infect
impair
reinfect
besid
vector
design
nucleas
recombinas
excis
hiv
provirus
remov
hiv
coreceptor
viral
vector
consid
ideal
tool
deliv
code
sequenc
bnab
antibodylikemolecul
eg
immunoadhesin
entryinhibit
peptid
name
exampl
excel
safeti
profil
human
clinic
trial
low
immunogen
high
stabil
vector
deriv
adenoassoci
virus
aav
becom
particularli
popular
purpos
aav
nonpathogen
replicationdefect
member
parvovirida
aav
vector
viral
openread
frame
replac
transgen
express
cassett
compris
gene
interest
control
element
albeit
clone
larger
transgen
gene
bnab
aav
vector
genom
sometim
challeng
due
limit
code
capac
plethora
natur
occur
serotyp
tailor
engin
capsid
avail
allow
nearli
free
choic
target
tissu
primeboost
vaccin
scheme
nonetheless
muscl
emerg
main
target
tissu
current
approach
result
contin
releas
bnab
molecul
employ
passiv
immun
vectortransduc
cell
clear
advantag
comparison
passiv
immun
recombin
protein
sinc
half
life
bioavail
requir
frequent
effect
lifelong
presenc
contrast
latter
howev
clinic
experi
aav
vector
overexpress
bnab
limit
far
singl
studi
initi
studi
base
result
studi
perform
human
mice
monkey
protect
demonstr
excel
summar
recent
review
advantag
use
vector
overexpress
bnab
combin
applic
multipl
bnab
latter
impress
decreas
risk
select
immuneescap
variant
hard
realiz
appli
recombin
bnab
due
cost
issu
concept
provid
bnab
support
patient
immun
system
fascin
shown
consider
promis
applic
recombin
bnab
directli
clinic
trial
protect
monkey
express
aav
vector
howev
foreign
host
immun
system
thu
prone
antiantibodi
induct
accord
semin
studi
martineznavio
colleagu
antibodi
direct
predominantli
variabl
region
respect
bnab
interestingli
magnitud
immun
respons
strongli
correl
matur
statu
antibodi
sequenc
ie
distanc
germlin
argu
highli
evolv
antibodi
easili
recogn
foreign
besid
factor
express
muscl
tissu
b
cell
may
contribut
use
immunesuppress
regim
avoid
transgen
express
profession
antigenpres
cell
induct
toler
target
hepatocyt
instead
muscl
cell
consid
potenti
solut
novel
gener
vector
may
reviv
concept
induc
bnab
activ
immun
result
alvachiv
trail
employ
primeboost
regimen
use
canarypox
vector
encod
hiv
env
gag
pro
prime
immun
system
follow
protein
applic
boost
immun
argu
inde
env
promis
target
activ
immun
approach
figur
given
recent
develop
capsid
engin
efficaci
antibodi
induct
viruslik
particl
fulli
compet
vector
display
epitop
protein
antigen
capsid
surfac
one
envis
prime
immun
system
aav
vector
display
env
epitop
viral
capsid
use
scaffold
antigen
display
time
induc
innat
immun
respons
vector
encod
time
solubl
env
immun
system
receiv
contin
boost
immun
intend
augment
induct
bnab
vivo
studi
show
approach
feasibl
env
antigen
envintrins
properti
like
immunosuppress
domain
present
may
limit
immunogen
neutral
antibodi
shown
correl
protect
mani
viral
infect
although
bnab
primari
heterolog
yet
induc
env
immunogen
avail
today
last
year
yield
crucial
insight
hivspecif
difficulti
vaccin
develop
recognit
bnab
identifi
subset
patient
chronic
infect
protect
infect
anim
model
reduc
viral
load
hivposit
patient
first
clinic
trial
emphas
import
bnab
respect
goal
vaccin
achiev
furthermor
detail
character
bnab
pave
way
toward
structurebas
revers
vaccinolog
approach
design
superior
immunogen
conserv
featur
nativ
env
additon
latest
env
immunogen
current
design
abl
engag
b
cell
order
stimul
pronounc
antibodyaffin
matur
characterist
mani
matur
bnab
futur
show
immunogen
suffici
gener
bnab
abl
protect
infect
strain
clade
nevertheless
vaccin
less
protect
also
reduc
number
new
infect
worth
pursu
meanwhil
vectorbas
express
bnab
option
achiev
high
express
level
passiv
immun
approach
would
avoid
high
cost
recombin
express
bnab
howev
develop
antiantibodi
still
issu
yet
known
broadli
neutral
nanobodi
behav
clinic
small
size
high
solubl
allow
much
better
express
also
expect
reduc
risk
antinanobodi
antibodi
